Company Profile

Adaptimmune Therapeutics plc (NASDAQ: ADAP)
5:00 PM UTC, 07/03/24
Last: $1.02 Change: -0.03 %Change: -2.86% Volume: 738,177
Detailed Quote
Open: $ 1.06   Volume: 738,177
High: $ 1.06   Yield(%) 0.00
Low: $ 1.00   P/E Ratio (ttm): n/a
Dividend ($): n/a   Market Cap ($): 268.27M
EPS ($) -0.73   Shares Out: 255.50M
M = Million B = Billion
Price Performance
% Price Change (last 4 weeks): 3.96
% Price Change (last 13 weeks): -25.00
% Price Change (last 26 weeks): 40.75
% Price Change (last 52 weeks): 12.59
% Price Change (year to date): 32.41
Management Effectiveness
Return on Equity (%): -188.34
Return on Assets (%): -37.39
Return on Invested Capital (%): -83.26
Profitability
Gross Profit Margin (%): 83.71
Net Profit Margin (%): -188.90
Operating Profit Margin (%): -227.66
Price & Volume
50-day Moving Average: $1.06
200-day Moving Average: $0.94
Avg. Daily Vol. (last 50 days): 1,541,140
Avg. Daily Vol. (last 200 days): 1,266,856
52-wk high: $2.05
52-wk low: $0.42
Bid: $1.04
Ask: $1.05
Company Information
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
Adaptimmune Therapeutics plc
60 Jubilee Avenue Milton Park
Abingdon OX OX14 4RX

Phone: 44.1235.430000
Fax: n/a
http://www.adaptimmune.com
Per Share Data
Earnings (1year) ($): -0.73
Annual Dividend ($): 0.00
Current P/E Ratio (ttm): n/a
Book Value ($): 0.17
Cash Flow ($): -0.46
Valuation Ratios
Price/Earnings (x): n/a
Price/Sales (x): 2.63
Price/Book (x): 4.56
Price/Cash Flow (x): n/a
Financial Strength
Quick Ratio (x): 2.85
Current Ratio (x): 2.85
LT Debt/Equity (x): 50.24
Total Debt/Equity (x): 63.87



Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2020 Wall Street Horizon, Inc.